脱氧胆酸与中重度CKD患者冠状动脉钙化的关联
本研究为临床试验参与者的队列分析,纳入112例中重度CKD患者,发现血清脱氧胆酸浓度>58ng/mL(中位数)与基线冠状动脉钙化体积评分独立正相关,与基线骨密度负相关,但与9个月后的钙化或骨密度变化无关。
要点
- 血清脱氧胆酸>58ng/mL与基线CAC体积评分独立正相关。
- 血清脱氧胆酸>58ng/mL与基线骨密度独立负相关。
- 脱氧胆酸与9个月CAC体积变化无显著关联。
核心结论
- 在中重度CKD患者中,较高的血清脱氧胆酸浓度与较大的基线冠状动脉钙化体积评分和较低的基线骨密度独立相关。
研究设计与样本
- 临床试验参与者的队列分析,纳入112例估算肾小球滤过率20-45mL/min/1.73m2的中重度CKD患者。
主要发现
- 血清脱氧胆酸浓度>58ng/mL(中位数)与基线CAC体积评分正相关(β=0.71;95% CI,0.26-1.16;P=0.003)。
- 血清脱氧胆酸浓度>58ng/mL与基线骨密度负相关(β=-20.3;95% CI,-1.5至-39.1;P=0.04)。
- 血清脱氧胆酸浓度>58ng/mL与9个月后CAC体积评分变化无显著关联(β=0.06;95% CI,-0.09至0.21;P=0.4)。
- 基线脱氧胆酸与9个月后骨密度变化的关系无统计学意义,但检验效能不足。
关键数值与推荐
- 血清脱氧胆酸浓度阈值为58ng/mL(中位数)。
- 协变量调整包括人口学特征、合并疾病、体重指数、eGFR及矿物质代谢标志物(钙、磷、维生素D、甲状旁腺激素、FGF23)。
临床怎么用
- 血清脱氧胆酸可能作为中重度CKD患者血管钙化和骨密度降低的关联标志物,但尚不能用于预测短期变化。
局限性
- 使用非空腹血清样本,脱氧胆酸浓度可能受时间和饮食影响。
- 评估CAC体积变化和骨密度变化的完整数据例数较少(分别为75例和59例)。
- 缺乏脱氧胆酸浓度随时间变化的数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vascular calcification is common among patients with chronic kidney disease (CKD), and it is associated with all-cause and cardiovascular disease mortality. Deoxycholic acid, a metabolite of circulating bile acids, is elevated in CKD and induces vascular mineralization and osteogenic differentiation in animal models. STUDY DESIGN: Cohort analysis of clinical trial participants. SETTING & PARTICIPANTS: 112 patients with moderate to severe CKD (estimated glomerular filtration rate, 20-45mL/min/1.73m2) who participated in a randomized controlled study to examine the effects of phosphate binders on vascular calcification. PREDICTOR: Serum deoxycholic acid concentration. OUTCOMES: Baseline coronary artery calcification (CAC) volume score and bone mineral density (BMD) and change in CAC volume score and BMD after 9 months. MEASUREMENTS: Deoxycholic acid was assayed in stored baseline serum samples using liquid chromatography-tandem mass spectrometry, CAC was measured using a GE-Imitron C150 scanner, and BMD was determined using computed tomographic scans of the abdomen with calibrated phantom of known density. RESULTS: Higher serum deoxycholic acid concentrations were significantly correlated with greater baseline CAC volume and lower baseline BMD. After adjusting for demographics, coexisting illness, body mass index, estimated glomerular filtration rate, and concentrations of circulating markers of mineral metabolism, including serum calcium, phosphorus, vitamin D, parathyroid hormone, and fibroblast growth factor 23, a serum deoxycholic acid concentration > 58ng/mL (the median) was positively associated with baseline CAC volume (β=0.71; 95% CI, 0.26-1.16; P=0.003) and negatively associated with baseline BMD (β = -20.3; 95% CI, -1.5 to -39.1; P=0.04). Serum deoxycholic acid concentration > 58ng/mL was not significantly associated with change in CAC volume score after 9 months (β=0.06; 95% CI, -0.09 to 0.21; P=0.4). The analysis for the relationship between baseline deoxycholic acid concentrations and change in BMD after 9 months was not statistically significant, but was underpowered. LIMITATIONS: The use of nonfasting serum samples is a limitation because deoxycholic acid concentrations may vary based on time of day and dietary intake. Few trial participants with complete data to evaluate the change in CAC volume score (n=75) and BMD (n=59). No data for changes in deoxycholic acid concentrations over time. CONCLUSIONS: Among patients with moderate to severe CKD, higher serum deoxycholic acid concentrations were independently associated with greater baseline CAC volume score and lower baseline BMD.
引用
- Jovanovich A, Isakova T, Block G, et al. Deoxycholic Acid, a Metabolite of Circulating Bile Acids, and Coronary Artery Vascular Calcification in CKD. Am J Kidney Dis. 2017. PMID: 28801122. doi:10.1053/j.ajkd.2017.06.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。